CSIMarket


Crinetics Pharmaceuticals Inc   (CRNX)
Other Ticker:  
 


 

Crinetics Pharmaceuticals Inc

CRNX's Financial Statements and Analysis



Crinetics Pharmaceuticals Inc increased III. Quarter net loss per share of $-0.78 compare to net loss per share of $-0.73 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.81 realized in previous quarter.


III. Quarter
Earnings Per Share Revenues
$ -0.78 $  0 Mill
$-0.05     Unch.    



Crinetics Pharmaceuticals Inc 's Revenue rose by 0 % in III. Quarter (Sep 30 2022) year on year, to $0 million and advanced by 4.33 % sequentially.


Crinetics Pharmaceuticals Inc is Expected to report next financial results on March 29, 2023.

More on CRNX's Income Statement



Crinetics Pharmaceuticals Inc 's in III. Quarter recorded net loss of $-41.925 million, an increase from net loss of $-27.851 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-42.375 million realized in previous quarter.

More on CRNX's Growth

In III. Quarter company's net cash and cash equivalents decreased by $0 million


Crinetics Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Crinetics Pharmaceuticals Inc payed $ -0.43 cash per share, on a free-cash flow basis .